Table 2 Thrombin generation parameters .... | American Society of Hematology

Table 2

Thrombin generation parameters

	−APC				+APC
	Lag time, minutes	ETP, nM · min	Peak, nM	Peak time, minutes	Lag time, minutes	ETP, nM · min	Peak, nM	Peak time, minutes
Controls	1.93 ± 0.34	821 ± 118	248 ± 34	3.78 ± 0.47	2.30 ± 0.35	211 ± 102	61 ± 30	4.29 ± 0.57
ET	1.94 ± 0.33	760 ± 177*	242 ± 54	3.63 ± 0.43	2.31 ± 0.37	286 ± 152†	81 ± 45†	4.31 ± 0.59
Negative (n = 29)	1.96 ± 0.31	800 ± 168	249 ± 58	3.71 ± 0.4	2.34 ± 0.39	255 ± 150	72 ± 48	4.39 ± 0.63
Heterozygous (n = 30)	1.91 ± 0.35	716 ± 179†	236 ± 49	3.56 ± 0.46*	2.29 ± 0.35	316 ± 150†	89 ± 42†	4.23 ± 0.57
PV	1.88 ± 0.36	725 ± 166†	235 ± 51	3.53 ± 0.58*	2.24 ± 0.45	311 ± 214†	92 ± 62†	4.15 ± 0.59
Negative (n = 3)	2.01 ± 0.08	856 ± 288	274 ± 84	3.70 ± 0.01	2.26 ± 0.25	375 ± 202	110 ± 104	4.22 ± 0.18
Heterozygous (n = 17)	1.87 ± 0.42	727 ± 88†	228 ± 41	3.61 ± 0.73*	2.20 ± 0.46	273 ± 199†	82 ± 60†	4.14 ± 0.67
Homozygous (n = 10)	1.85 ± 0.32	684 ± 217†	236 ± 56	3.38 ± 0.40†	2.30 ± 0.51	352 ± 202†	103 ± 55†	4.14 ± 0.55

	−APC				+APC
	Lag time, minutes	ETP, nM · min	Peak, nM	Peak time, minutes	Lag time, minutes	ETP, nM · min	Peak, nM	Peak time, minutes
Controls	1.93 ± 0.34	821 ± 118	248 ± 34	3.78 ± 0.47	2.30 ± 0.35	211 ± 102	61 ± 30	4.29 ± 0.57
ET	1.94 ± 0.33	760 ± 177*	242 ± 54	3.63 ± 0.43	2.31 ± 0.37	286 ± 152†	81 ± 45†	4.31 ± 0.59
Negative (n = 29)	1.96 ± 0.31	800 ± 168	249 ± 58	3.71 ± 0.4	2.34 ± 0.39	255 ± 150	72 ± 48	4.39 ± 0.63
Heterozygous (n = 30)	1.91 ± 0.35	716 ± 179†	236 ± 49	3.56 ± 0.46*	2.29 ± 0.35	316 ± 150†	89 ± 42†	4.23 ± 0.57
PV	1.88 ± 0.36	725 ± 166†	235 ± 51	3.53 ± 0.58*	2.24 ± 0.45	311 ± 214†	92 ± 62†	4.15 ± 0.59
Negative (n = 3)	2.01 ± 0.08	856 ± 288	274 ± 84	3.70 ± 0.01	2.26 ± 0.25	375 ± 202	110 ± 104	4.22 ± 0.18
Heterozygous (n = 17)	1.87 ± 0.42	727 ± 88†	228 ± 41	3.61 ± 0.73*	2.20 ± 0.46	273 ± 199†	82 ± 60†	4.14 ± 0.67
Homozygous (n = 10)	1.85 ± 0.32	684 ± 217†	236 ± 56	3.38 ± 0.40†	2.30 ± 0.51	352 ± 202†	103 ± 55†	4.14 ± 0.55

The results (mean ± SD) obtained in the absence and presence of APC are shown according to disease type (ET or PV) and JAK2^V617F mutational status.

P < .05 versus controls.

P < .01 versus controls.